EUVIMEDEUVIMED entdecken
Multizentrische Studie

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer

Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yuko Toyoda, Yugo Matsumura, Seiya Ichihara, Takeshi Imakura, Rikako Matsumoto, Ryohiko Ozaki, Ei Ogawa und 9 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02586-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Yuki Tsukazaki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15, Kuramoto-Cho, Tokushima, …. Hauptthemen laut MEDLINE: Lung Neoplasms, Granulocyte Colony-Stimulating Factor, Small Cell Lung Carcinoma, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) has the potential to attenuate the anti-tumor immune responses of T-cells by increasing immune suppressive neutrophils and myeloid-derived suppressor cells. However, the clinical impact of G-CSF on the efficacy of immunotherapy remains unknown. This multi-center retrospective analysis evaluated the impact of G-CSF in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with chemo-immunotherapy. METHODS: We analyzed 65 patients with ES-SCLC who completed four cycles of induction chemo-immunotherapy and evaluated the effects of G-CSF on progression-free survival (PFS), overall survival (OS), and a durable response to immunotherapy (defined as PFS ≥ 12 months). RESULTS: Fifty patients (76.9%) received ≥ 1 dose of G-CSF. The PFS of the patients with G-CSF was poorer than that of the patients without G-CSF (median PFS 8.3 vs. 4.9 months, p = 0.009). The OS of the patients with G-CSF tended to be shorter, but not statistically significant, than that of the patients without G-CSF (median OS 24.3 vs. 16.4 months, p = 0.137). In the multivariate analysis, G-CSF administration was associated with poorer PFS (hazard ratio 2.78, 95% CI 1.36-5.69, p = 0.005) and was identified as a determinant of a durable response (odds ratio 0.18, 95% CI 0.04-0.80, p = 0.024). These results were consistent with other definitions of G-CSF administration (administration of ≥ 1 dose of pegfilgrastim, or either ≥ 5 doses of filgrastim or ≥ 1 dose of pegfilgrastim). CONCLUSIONS: G-CSF has the potential to attenuate the efficacy of immunotherapy; therefore, the indication for G-CSF during chemo-immunotherapy should be carefully considered for ES-SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsGranulocyte Colony-Stimulating FactorSmall Cell Lung CarcinomaImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultProgression-Free SurvivalAged, 80 and overNeoplasm Staging

Stichwörter der Autor:innen

Chemo-immunotherapyExtensive-stage small-cell lung cancerGranulocyte colony-stimulating factor

Substanzen

Granulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15, Kuramoto-Cho, Tokushima, 770-8503, Japan.
  • Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, 3-18-15, Kuramoto-Cho, Tokushima, 770-8503, Japan. ogino@tokushima-u.ac.jp.
  • Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, 1-2-25 Asakuranishimachi, Kochi, 780-8507, Japan.
  • Department of Respiratory Medicine, Tokushima Prefectural Central Hospital, 1-10-3, Kuramoto-Cho, Tokushima, 770-8539, Japan.
  • Department of Respiratory Medicine, Tokushima Municipal Hospital, 2-34 Kitajosanjima-Cho, Tokushima, 770-0812, Japan.
  • Department of Internal Medicine, Japanese Red Cross Kochi Hospital, 1-4-63-11, Hadaminamimachi, Kochi, 780-8562, Japan.

Zitieren

APA

Tsukazaki, Y., Ogino, H., Okano, Y., Kakiuchi, S., Harada, S., Toyoda, Y., Matsumura, Y., Ichihara, S., Imakura, T., Matsumoto, R., Ozaki, R., Ogawa, E., Morita, Y., Mitsuhashi, A., Yabuki, Y., Yoneda, H., Hanibuchi, M., Hase, K., Takeuchi, E., …, & Nishioka, Y. (2024). Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02586-0

Vancouver

Tsukazaki Y, Ogino H, Okano Y, Kakiuchi S, Harada S, Toyoda Y, et al. Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02586-0

BibTeX
@article{Tsukazaki2024,
  author = {Tsukazaki, Yuki and Ogino, Hirokazu and Okano, Yoshio and Kakiuchi, Soji and Harada, Shoko and Toyoda, Yuko and Matsumura, Yugo and Ichihara, Seiya and Imakura, Takeshi and Matsumoto, Rikako and Ozaki, Ryohiko and Ogawa, Ei and Morita, Yutaka and Mitsuhashi, Atsushi and Yabuki, Yohei and Yoneda, Hiroto and Hanibuchi, Masaki and Hase, Kayoko and Takeuchi, Eiji and Haku, Takashi and Nishioka, Yasuhiko},
  title = {Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02586-0}
}
Kostenlos starten →